12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Laquinimod: Phase IIa data

A double-blind, international Phase IIa trial in 180 patients with moderate to severe CD showed that once-daily 0.5 mg oral laquinimod improved remission (48.3% vs. 15.9%) and response (62.1% vs. 34.9%) rates from baseline after 8 weeks vs. placebo. The 1 mg dose of laquinimod led to a 26.7% remission rate and a 53.3% response rate. Teva said the 1.5 and 2 mg doses of laquinimod had no effect on response or remission rates. The company said the study was exploratory in nature...

Read the full 394 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >